Advertisement
Screener

Cumberland Pharmaceuticals Inc. (CPIX) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Cumberland Pharmaceuticals Inc. Comprehensive Income

Cumberland Pharmaceuticals Inc. (CPIX) reported Comprehensive Income of -$1.07 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-22.

Discontinued › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2020-12-10

  • Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2020-03-31 was -$1.07M.
  • Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-12-31 was -$972.35K.
  • Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-09-30 was -$1.97M.
  • Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-06-30 was -$566.81K.
  • Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was -$8.05M.
  • Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$1.00M, a 249.59% decline from fiscal 2015.
  • Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2015 was $671.11K, a 71.59% decline from fiscal 2014.
  • Cumberland Pharmaceuticals Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2014 was $2.36M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2020-03-31-$1.07M
10-Q · filed 2020-05-22
-$2.04M
derived: sum of 2 quarters · filed 2020-12-10
-$4.00M
derived: sum of 3 quarters · filed 2020-12-10
-$4.57M
derived: sum of 4 quarters · filed 2020-12-10
2019-12-31-$972.35K
derived: 8-K 12 month − 10-Q 9 month · filed 2020-12-10
-$2.94M
derived: sum of 2 quarters · filed 2020-12-10
-$3.51M
derived: sum of 3 quarters · filed 2020-12-10
-$3.55M
8-K · filed 2020-12-10
2019-09-30-$1.97M
10-Q · filed 2019-11-13
-$2.53M
derived: sum of 2 quarters · filed 2019-11-13
-$2.57M
10-Q · filed 2019-11-13
-$4.81M
derived: sum of 4 quarters · filed 2020-12-10
2019-06-30-$566.81K
10-Q · filed 2019-08-14
-$607.23K
10-Q · filed 2019-08-14
-$2.84M
derived: sum of 3 quarters · filed 2020-12-10
-$4.51M
derived: sum of 4 quarters · filed 2020-12-10
2019-03-31-$40.42K
10-Q · filed 2020-05-22
-$2.28M
derived: sum of 2 quarters · filed 2020-12-10
-$3.94M
derived: sum of 3 quarters · filed 2020-12-10
-$4.69M
derived: sum of 4 quarters · filed 2020-12-10
2018-12-31-$2.24M
derived: 8-K 12 month − 10-Q 9 month · filed 2020-12-10
-$3.90M
derived: sum of 2 quarters · filed 2020-12-10
-$4.65M
derived: sum of 3 quarters · filed 2020-12-10
-$7.04M
8-K · filed 2020-12-10
2018-09-30-$1.66M
10-Q · filed 2019-11-13
-$2.41M
derived: sum of 2 quarters · filed 2019-11-13
-$4.80M
10-Q · filed 2019-11-13
-$5.62M
derived: sum of 4 quarters · filed 2020-03-20
2018-06-30-$745.45K
10-Q · filed 2019-08-14
-$3.14M
10-Q · filed 2019-08-14
-$3.96M
derived: sum of 3 quarters · filed 2020-03-20
-$4.72M
derived: sum of 4 quarters · filed 2020-03-20
2018-03-31-$2.39M
10-Q · filed 2019-05-15
-$3.21M
derived: sum of 2 quarters · filed 2020-03-20
-$3.97M
derived: sum of 3 quarters · filed 2020-03-20
-$9.15M
derived: sum of 4 quarters · filed 2020-03-20
2017-12-31-$821.80K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20
-$1.58M
derived: sum of 2 quarters · filed 2020-03-20
-$6.76M
derived: sum of 3 quarters · filed 2020-03-20
-$8.05M
10-K · filed 2020-03-20
2017-09-30-$757.24K
10-Q · filed 2018-11-14
-$5.93M
derived: sum of 2 quarters · filed 2018-11-14
-$7.23M
10-Q · filed 2018-11-14
-$8.00M
derived: sum of 4 quarters · filed 2019-03-12
2017-06-30-$5.18M
10-Q · filed 2018-08-14
-$6.47M
10-Q · filed 2018-08-14
-$7.24M
derived: sum of 3 quarters · filed 2019-03-12
-$7.15M
derived: sum of 4 quarters · filed 2019-03-12
2017-03-31-$1.29M
10-Q · filed 2018-05-09
-$2.06M
derived: sum of 2 quarters · filed 2019-03-12
-$1.97M
derived: sum of 3 quarters · filed 2019-03-12
-$2.03M
derived: sum of 4 quarters · filed 2019-03-12
2016-12-31-$769.93K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12
-$674.44K
derived: sum of 2 quarters · filed 2019-03-12
-$735.38K
derived: sum of 3 quarters · filed 2019-03-12
-$1.00M
10-K · filed 2019-03-12
2016-09-30$95.49K
10-Q · filed 2017-11-08
$34.55K
derived: sum of 2 quarters · filed 2017-11-08
-$234.01K
10-Q · filed 2017-11-08
-$105.41K
derived: sum of 4 quarters · filed 2018-03-09
2016-06-30-$60.94K
10-Q · filed 2017-08-09
-$329.50K
10-Q · filed 2017-08-09
-$200.90K
derived: sum of 3 quarters · filed 2018-03-09
-$79.20K
derived: sum of 4 quarters · filed 2018-03-09
2016-03-31-$268.56K
10-Q · filed 2017-05-15
-$139.96K
derived: sum of 2 quarters · filed 2018-03-09
-$18.26K
derived: sum of 3 quarters · filed 2018-03-09
$376.04K
derived: sum of 4 quarters · filed 2018-03-09
2015-12-31$128.60K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09
$250.30K
derived: sum of 2 quarters · filed 2018-03-09
$644.60K
derived: sum of 3 quarters · filed 2018-03-09
$671.11K
10-K · filed 2018-03-09
2015-09-30$121.70K
10-Q · filed 2016-11-03
$516.00K
derived: sum of 2 quarters · filed 2016-11-03
$542.51K
10-Q · filed 2016-11-03
$1.19M
derived: sum of 4 quarters · filed 2017-03-13
2015-06-30$394.30K
10-Q · filed 2016-08-05
$420.81K
10-Q · filed 2016-08-05
$1.07M
derived: sum of 3 quarters · filed 2017-03-13
$1.80M
derived: sum of 4 quarters · filed 2017-03-13
2015-03-31$26.51K
10-Q · filed 2016-05-13
$675.08K
derived: sum of 2 quarters · filed 2017-03-13
$1.40M
derived: sum of 3 quarters · filed 2017-03-13
$2.11M
derived: sum of 4 quarters · filed 2017-03-13
2014-12-31$648.56K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13
$1.38M
derived: sum of 2 quarters · filed 2017-03-13
$2.09M
derived: sum of 3 quarters · filed 2017-03-13
$2.36M
10-K · filed 2017-03-13
2014-09-30$729.18K
10-Q · filed 2015-11-06
$1.44M
derived: sum of 2 quarters · filed 2015-11-06
$1.71M
10-Q · filed 2015-11-06
$202.51K
derived: sum of 4 quarters · filed 2016-03-14
2014-06-30$709.54K
10-Q · filed 2015-08-07
$984.72K
10-Q · filed 2015-08-07
-$526.68K
derived: sum of 3 quarters · filed 2016-03-14
-$1.36M
derived: sum of 4 quarters · filed 2016-03-14
2014-03-31$275.18K
10-Q · filed 2015-05-15
-$1.24M
derived: sum of 2 quarters · filed 2016-03-14
-$2.07M
derived: sum of 3 quarters · filed 2016-03-14
-$2.72M
derived: sum of 4 quarters · filed 2016-03-14
2013-12-31-$1.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14
-$2.34M
derived: sum of 2 quarters · filed 2016-03-14
-$2.99M
derived: sum of 3 quarters · filed 2016-03-14
-$2.15M
10-K · filed 2016-03-14
2013-09-30-$832.50K
10-Q · filed 2014-11-07
-$1.48M
derived: sum of 2 quarters · filed 2014-11-07
-$640.02K
10-Q · filed 2014-11-07
$1.15M
derived: sum of 4 quarters · filed 2015-03-09
2013-06-30-$648.85K
10-Q · filed 2014-08-08
$192.47K
10-Q · filed 2014-08-08
$1.99M
derived: sum of 3 quarters · filed 2015-03-09
$3.85M
derived: sum of 4 quarters · filed 2015-03-09
2013-03-31$841.33K
10-Q · filed 2014-05-12
$2.64M
derived: sum of 2 quarters · filed 2015-03-09
$4.50M
derived: sum of 3 quarters · filed 2015-03-09
$6.23M
derived: sum of 4 quarters · filed 2015-03-09
2012-12-31$1.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09
$3.66M
derived: sum of 2 quarters · filed 2015-03-09
$5.39M
derived: sum of 3 quarters · filed 2015-03-09
$5.81M
10-K · filed 2015-03-09
2012-09-30$1.86M
10-Q · filed 2013-11-06
$3.60M
derived: sum of 2 quarters · filed 2013-11-06
$4.01M
10-Q · filed 2013-11-06
2012-06-30$1.74M
10-Q · filed 2013-08-09
$2.15M
10-Q · filed 2013-08-09
2012-03-31$413.84K
10-Q · filed 2013-05-08
2011-12-31$5.63M
10-K · filed 2014-03-11
2010-12-31$2.43M
10-K · filed 2013-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Immuneering Corp (IMRX)United States$0.113B-12.51
Quantum Cyber N.V. (QUCY)$0.113B
MEDICINOVA INC (MNOV)United States$0.130B-6.04
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31